Physician profile
Mark A Demoss
NPI 1538172960
$2,973.09
in general payments reported to CMS, 2019-2025
19 companies · $76.49 in 2025
The $76.49 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $337 · 2021: $625 · 2022: $587 · 2023: $585 · 2024: $339 · 2025: $76.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $776.95 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $439.11 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $334.71 | 2021-2024 | Azstarys |
| Glaxosmithkline, LLC. | $316.56 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Supernus Pharmaceuticals, INC. | $274.32 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $141.00 | 2019-2022 | |
| Neos Therapeutics, LP | $135.94 | 2019-2022 | |
| Cranial Technologies, INC | $104.56 | 2022-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $84.94 | 2020-2023 | M-M-R II, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $71.41 | 2020-2022 | |
| Genentech USA, INC. | $59.25 | 2019-2021 | |
| Adlon Therapeutics L.P. | $43.37 | 2020 | |
| Pfizer INC. | $38.78 | 2019-2021 | |
| Shire North American Group INC | $38.47 | 2019 | |
| Collegium Pharmaceutical, INC. | $37.49 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $22.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.77 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.17 | 2024 | |
| Seqirus USA INC | $16.36 | 2023 | Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Demoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.